Verdiva Bio Launches With $411 Million Series A to Advance Cardiometabolic Therapies
Verdiva Bio, a London-based clinical-stage biopharmaceutical company, has launched with an oversubscribed $411 million Series A financing round. The investment was co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital.
The substantial funding will support Verdiva Bio’s development of innovative therapies targeting obesity and other cardiometabolic disorders. The company’s portfolio includes a phase 2-ready, once-weekly oral GLP-1 receptor agonist and a once-weekly oral amylin agonist, both designed for weight loss and maintenance.
Verdiva Bio acquired global development and commercialization rights to these assets, excluding Greater China and South Korea, from Sciwind Biosciences in 2024. This strategic move aims to advance next-generation treatments that offer improved patient convenience and efficacy.
CEO Khurem Farooq, formerly of Aiolos Bio and Gyroscope Therapeutics, leads the company alongside a team of experienced drug developers and biotech professionals. The leadership team is committed to addressing significant unmet medical needs in the cardiometabolic health sector.
The Series A financing marks one of the largest initial funding rounds in European biopharma, underscoring investor confidence in Verdiva Bio’s approach to transforming cardiometabolic care. The company plans to utilize the funds to progress clinical development and expand its portfolio of therapies.
Verdiva Bio’s innovative oral therapies aim to enhance patient adherence and accessibility, potentially offering more sustainable solutions for weight management and related complications. The company’s approach reflects a growing trend in developing patient-friendly treatment options in the biopharmaceutical industry.
With this significant financial backing, Verdiva Bio is poised to make substantial advancements in the treatment of obesity and cardiometabolic disorders, striving to improve health outcomes for patients worldwide.
